Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.

Bibliographic Details
Published in:Journal of Clinical Oncology Vol. 43; pp. 159 - 447
Main Authors: Freedland, Stephen J., Gleave, Martin, De Giorgi, Ugo, Rannikko, Antti, Sridharan, Swetha, Brasso, Klaus, Woo, Henry H., Gómez Caamaño, Antonio, Nordquist, Luke, Tang, Yiyun, Croitoru, Ruslan, Rosales, Matt, Kalac, Matko, Peraud, Olivier, Wang, Fong, Shore, Neal D.
Format: Journal Article
Published: American Society of Clinical Oncology 2/10/2025 Supplement5
Online Access:View this record in EBSCOhost